Key result
A third-generation quantitative cTnT point-of-care test showed 75% sensitivity and 100% specificity compared to the laboratory assay, missing levels between 0.03 and 0.10 ng/mL.
Why the study?
Does a third generation quantitative cardiac troponin T point-of-care test accurately detect elevated cTnT compared to a laboratory assay in patients with suspected acute coronary syndromes?
Cross-Sectional (n=133)
No
Does a third generation quantitative cardiac troponin T point-of-care test accurately detect elevated cTnT compared to a laboratory assay in patients with suspected acute coronary syndromes?
The third-generation cTnT point-of-care test has high specificity but insufficient sensitivity to detect low-level troponin elevations (0.03-0.10 ng/mL) compared to laboratory assays in patients with suspected acute coronary syndromes.
Answers are grounded in this paper and cite their sources.
POCT missed 25% of lab-positive troponin elevations; leaves open its reliability for ruling out injury pending prospective validation.
We compared a third generation quantitative cardiac troponin T (cTnT) point-of-care testing (POCT) from Roche Diagnostics with the laboratory assay (Roche Elecsys 2010 immunoassay analyser). Heparin-treated blood and serum were collected simultaneously in 133 unselected patients (mean age 62 +/- 14 years, 38% females) presenting to our hospital with possible cardiac chest pain. Results of the POCT were measured against the laboratory-based assay considered as the gold standard. There were 18 POCT positive versus 24 laboratory assay positive (> or = 0.03 ng/mL) patients. POCT was falsely negative in six patients, with values between 0.03 and 0.1 ng/mL. The POCT had a sensitivity of 75%, specificity of 100%, positive predictive value of 100%, negative predictive value of 95% and a total accuracy of 95%; kappa = 0.831 (P < 0.001). There was good correlation between the values of POCT and the laboratory assay: Y = 1.195X + 0.002, r2 = 0.94 (P < 0.0001). Whereas cTnT levels > 0.1 mg/mL were reliably detected with this current generation of POCT, cTnT levels between 0.03 and 0.10 ng/mL were not. Future generations of devices will need to improve sensitivity to reliably risk stratify patients with suspected acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
Hallani et al. (2005) conducted a cross-sectional in suspected acute coronary syndromes (n=133). Third generation quantitative cardiac troponin T (cTnT) point-of-care testing (POCT) vs. Laboratory assay (Roche Elecsys 2010 immunoassay analyser) was evaluated on Detection of serum cardiac troponin T ≥ 0.03 ng/mL (kappa 0.831, p=< 0.001). A third-generation quantitative cTnT point-of-care test showed 75% sensitivity and 100% specificity compared to the laboratory assay, missing levels between 0.03 and 0.10 ng/mL.
Synapse has enriched 10 related papers. Consider them for comparative context: